Discover 249 paid clinical trials in Dover, Delaware. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 249
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
for
Multiple Myeloma
Location: Newark DE, Baltimore MD, Bethesda MD, Fort Belvoir VA,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT05552222
Phase3, Recruiting
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
for
Non-Muscle Invasive Bladder Urothelial Carcinoma,
Location: Newark DE, Chadds Ford PA, Hershey PA, Middletown NJ,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06770582
Phase2, Recruiting
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
for
Large B-cell Lymphoma
Location: Newark DE, Baltimore MD, Philadelphia PA,
Sponsor: Allogene Therapeutics
Sex: All
Age: 18+
Code: NCT06500273
Phase2, Recruiting
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
for
Lymphoma, Malignant Solid Neoplasm
Location: Newark DE, Danville PA, Wilkes-Barre PA,
Sponsor: University of Rochester
Sex: All
Age: 18+
Code: NCT05006482
Phase3, Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
for
Carcinoma, Non-Small-Cell Lung
Location: Newark DE, Philadelphia PA, Baltimore MD,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT06667076
Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Location: Newark DE, Sewell NJ, West Chester PA, Philadelphia PA,
Sponsor: National Cancer Institute (NCI)
Sex: Female
Age: 18+
Code: NCT05256225
Phase3, Recruiting
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
for
Astrocytoma, IDH-Mutant, Grade 3
Location: Newark DE, Chadds Ford PA, Philadelphia PA,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 12+
Code: NCT07215910
Phase3, Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
for
Non-small Cell Lung Cancer (NSCLC)
Location: Newark DE, New York NY, Westbury NY, Norfolk VA,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT07361497
Phase3, Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
for
Carcinoma, Non-Small-Cell Lung
Location: Newark DE, Columbia MD, York PA, White Plains NY,
Sponsor: Mirati Therapeutics Inc.
Sex: All
Age: 18+
Code: NCT06875310
Phase3, Recruiting
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
for
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative,
Location: Newark DE, Washington D.C. DC, New Hyde Park NY,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT03739814
Phase2, Recruiting
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
for
Advanced Hepatocellular Carcinoma,
Location: Newark DE, Wilmington DE, Chadds Ford PA, Alexandria VA,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT07166406
Phase3, Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
for
Metastatic Castration-resistant Prostate Cancer
Location: Newark DE, Baltimore MD, Leesburg VA, New York NY,
Sponsor: Amgen
Sex: Male
Age: 18+
Code: NCT07213674
Phase3, Recruiting
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
for
Extensive Stage Lung Small Cell Carcinoma,
Location: Newark DE, Baltimore MD, Tappahannock VA, Richmond VA,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT06769126
Phase2, Recruiting
Education & Mentorship of Advanced Practice Providers to Increase Community-based Research Within the NCORP Network, COACH-APP Trial
for
Other
Location: Newark DE, Winston-Salem NC, Scarborough ME,
Sponsor: Wake Forest University Health Sciences
Sex: All
Age: 18+
Code: NCT06904391
Recruiting
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Location: Newark DE, Sewell NJ, Philadelphia PA, Cherry Hill NJ,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 65+
Code: NCT07321652
Phase3, Recruiting
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Location: Newark DE, Wilmington DE, Chadds Ford PA,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT06958328
Phase3, Recruiting
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
for
Urothelial Cancer, Urinary Bladder Neoplasms
Location: Newark DE, Norfolk VA, Fort Wayne IN, Nashville TN,
Sponsor: Astellas Pharma Global Development, Inc.
Sex: All
Age: 18+
Code: NCT07566156
Phase3, Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
for
Breast Neoplasms
Location: Newark DE, Philadelphia PA, Allentown PA, New York NY,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT06926868
Phase2, Phase3, Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
for
Leukemia, Myeloid, Acute
Location: Newark DE, Philadelphia PA, Bethesda MD, New York NY,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT06852222
Phase3, Recruiting
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
for
Breast Neoplasms
Location: Newark DE, York PA, New Brunswick NJ, Jamaica NY,